Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease
dc.catalogador | grr | |
dc.contributor.author | Espino Espino, Alberto Antonio | |
dc.contributor.author | Villagran Torres, Andrea Alejandra | |
dc.contributor.author | Vollrath Reyes, Valeska Yolanda | |
dc.contributor.author | Hanckes Mayo, Maria Paulina | |
dc.contributor.author | Salas Ocaranza, Roberto Ignacio | |
dc.contributor.author | Farah Samaan, Andrea Catherina | |
dc.contributor.author | Solis, Nancy | |
dc.contributor.author | Pizarro Rojas, Margarita Alicia | |
dc.contributor.author | Escalona Perez, Alex Gamaliel | |
dc.contributor.author | Boza Wilson, Camilo | |
dc.contributor.author | Perez, Gustavo | |
dc.contributor.author | Carrasco, Gonzalo | |
dc.contributor.author | Padilla, Orlando | |
dc.contributor.author | Francisco Miguel, Juan | |
dc.contributor.author | Nervi Oddone, Flavio | |
dc.contributor.author | Chavez Tapia, Norberto C. | |
dc.contributor.author | Arab Verdugo, Juan Pablo | |
dc.contributor.author | Alvarez Lobos, Manuel Marcelo | |
dc.contributor.author | Arrese Jimenez, Marco Antonio | |
dc.contributor.author | Riquelme Perez, Arnoldo Javier | |
dc.date.accessioned | 2024-08-06T21:53:19Z | |
dc.date.available | 2024-08-06T21:53:19Z | |
dc.date.issued | 2011 | |
dc.description.abstract | Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis. Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism. Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 +/- 4.82) compared to controls (14.26 +/- 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 +/- 4.35) compared to patients without liver fibrosis (10.61 +/- 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6). Conclusions. Morbidly obese patients had significantly Lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients. | |
dc.description.funder | Fondo Nacional de Ciencia y Tecnologia de Chile (FONDECYT) | |
dc.fechaingreso.objetodigital | 2024-08-06 | |
dc.format.extent | 9 pƔginas | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.1016/S1665-2681(19)31518-2 | |
dc.identifier.issn | 1665-2681 | |
dc.identifier.pubmedid | 21911891 | |
dc.identifier.uri | https://doi.org/10.1016/S1665-2681(19)31518-2 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/87305 | |
dc.identifier.wosid | WOS:000296672600012 | |
dc.information.autoruc | Escuela de Medicina; Espino Espino, Alberto Antonio; 0000-0001-5707-6290; 146018 | |
dc.information.autoruc | Escuela de Medicina; Villagran Torres, Andrea Alejandra; S/I; 1004414 | |
dc.information.autoruc | Escuela de Medicina; Vollrath Reyes, Valeska Yolanda; S/I; 2185 | |
dc.information.autoruc | Escuela de Medicina; Hanckes Mayo,Maria Paulina; S/I; 149931 | |
dc.information.autoruc | Escuela de Medicina; Salas Ocaranza, Roberto Ignacio; S/I; 149947 | |
dc.information.autoruc | Escuela de Medicina; Farah Samaan, Andrea Catherina; S/I; 134185 | |
dc.information.autoruc | Escuela de Medicina; Pizarro Rojas, Margarita Alicia; 0000-0003-3063-3143; 102250 | |
dc.information.autoruc | Escuela de Medicina; Escalona Perez, Alex Gamaliel; 0000-0001-5808-3679; 94025 | |
dc.information.autoruc | Escuela de Medicina; Boza Wilson, Camilo; S/I; 761 | |
dc.information.autoruc | Escuela de Medicina; Nervi Oddone, Flavio; 0000-0002-6642-7985; 99156 | |
dc.information.autoruc | Escuela de Medicina; Arab Verdugo, Juan Pablo; 0000-0002-8561-396X; 132745 | |
dc.information.autoruc | Escuela de Medicina; Alvarez Lobos, Manuel Marcelo; S/I; 6131 | |
dc.information.autoruc | Escuela de Medicina; Arrese Jimenez, Marco Antonio; 0000-0002-0499-4191; 76095 | |
dc.information.autoruc | Escuela de Medicina; Riquelme Perez, Arnoldo Javier; 0000-0002-8259-8960; 3538 | |
dc.issue.numero | 4 | |
dc.language.iso | en | |
dc.nota.acceso | contenido completo | |
dc.pagina.final | 501 | |
dc.pagina.inicio | 493 | |
dc.publisher | Elsevier EspaƱa | |
dc.revista | Annals of Hepatology | |
dc.rights | acceso abierto | |
dc.rights.license | CC BY-NC-ND 4.0 Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Plasminogen activator inhibitor type 1 | |
dc.subject | Single nucleotide polymorphisms | |
dc.subject | Liver fibrosis | |
dc.subject | Non-alcoholic fatty liver disease | |
dc.subject | Steatosis | |
dc.subject.ddc | 610 | |
dc.subject.dewey | Medicina y salud | es_ES |
dc.subject.ods | 03 Good health and well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease | |
dc.type | artĆculo | |
dc.volumen | 10 | |
sipa.codpersvinculados | 14818 | |
sipa.codpersvinculados | 32517 | |
sipa.codpersvinculados | 72216 | |
sipa.codpersvinculados | 102063 | |
sipa.codpersvinculados | 5510 | |
sipa.codpersvinculados | 102379 | |
sipa.codpersvinculados | 146018 | |
sipa.codpersvinculados | 1004414 | |
sipa.codpersvinculados | 2185 | |
sipa.codpersvinculados | 149931 | |
sipa.codpersvinculados | 149947 | |
sipa.codpersvinculados | 134185 | |
sipa.codpersvinculados | 102250 | |
sipa.codpersvinculados | 94025 | |
sipa.codpersvinculados | 761 | |
sipa.codpersvinculados | 99156 | |
sipa.codpersvinculados | 132745 | |
sipa.codpersvinculados | 6131 | |
sipa.codpersvinculados | 76095 | |
sipa.codpersvinculados | 3538 | |
sipa.trazabilidad | WOS;05-06-2021 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 1-s2.0-S1665268119315182-main.pdf
- Size:
- 203.52 KB
- Format:
- Adobe Portable Document Format
- Description: